Syndax director granted 48,000 restricted stock units

Syndax Pharmaceuticals director Dennis Podlesak reported an equity award on this Form 4.

Accepted by SEC EDGAR 02/06/2026 - 04:14 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Syndax Pharmaceuticals director Dennis Podlesak reported an equity award on this Form 4. On February 4, 2026, he was granted 48,000 restricted stock units at a price of $0 per share. These units vest one year from the grant date.

The shares underlying the restricted stock units will only be delivered, and may not be transferred or sold, until the earlier of a separation from service, death, disability, or a change in control. After this grant, Podlesak beneficially owns 239,763 shares of common stock, held directly.

Insider Trade Summary

Grant/Award: 48,000 shares

Grant/Award 1 txn

Insider Podlesak Dennis

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	48,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 239,763 shares (Direct)

Holdings Before and After: Common Stock, 191,763 to 239,763 shares (Direct)

Footnotes (1)

1. F1. Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Syndax Pharmaceuticals (SNDX) report for Dennis Podlesak?

Dennis Podlesak reported receiving an award of 48,000 restricted stock units on February 4, 2026. The award was recorded at a price of $0 per share and increased his directly held beneficial ownership to 239,763 shares of Syndax Pharmaceuticals common stock.

What are the vesting terms of Dennis Podlesak’s 48,000 restricted stock units at Syndax (SNDX)?

The 48,000 restricted stock units granted to Dennis Podlesak vest one year from the grant date. The underlying shares will not be delivered, and cannot be transferred or sold, until vesting and the earlier of separation from service, death, disability, or a change in control.

How many Syndax (SNDX) shares does Dennis Podlesak beneficially own after this Form 4 transaction?

Following the reported award, Dennis Podlesak beneficially owns 239,763 shares of Syndax Pharmaceuticals common stock. This ownership is reported as direct, reflecting his holdings after the 48,000 restricted stock units were granted on February 4, 2026.

Was cash paid for Dennis Podlesak’s Syndax (SNDX) restricted stock unit award?

No cash was paid for the award; the 48,000 restricted stock units were reported at a price of $0 per share. This indicates a compensatory equity grant rather than an open-market purchase, consistent with typical director or executive stock-based compensation.

When can Dennis Podlesak sell the shares from his Syndax (SNDX) restricted stock units?

The shares underlying the restricted stock units cannot be transferred or sold until they are delivered. Delivery occurs at the earlier of a separation from service, death, disability, or a change in control, following the one-year vesting period from the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Podlesak Dennis

(Last) (First) (Middle)

C/O SYNDAX PHARMACEUTICALS, INC.

730 THIRD AVENUE, FLOOR 9

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Syndax Pharmaceuticals Inc [ SNDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		48,000(1)	A	$0	239,763	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

	/s/ Michael A. Metzger, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.